1,384 reports of this reaction
8.1% of all VISMODEGIB reports
#2 most reported adverse reaction
ALOPECIA is the #2 most commonly reported adverse reaction for VISMODEGIB, manufactured by Genentech, Inc.. There are 1,384 FDA adverse event reports linking VISMODEGIB to ALOPECIA. This represents approximately 8.1% of all 17,013 adverse event reports for this drug.
Patients taking VISMODEGIB who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is moderately reported among VISMODEGIB users, representing a notable but not dominant share of adverse events.
In addition to alopecia, the following adverse reactions have been reported for VISMODEGIB:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 1,384 FDA reports for VISMODEGIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 8.1% of all adverse event reports for VISMODEGIB, making it one of the most commonly reported side effect.
If you experience alopecia while taking VISMODEGIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.